Cidara Historical Financial Ratios
CDTX Stock | USD 20.21 0.01 0.05% |
Cidara Therapeutics is presently reporting on over 108 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 111 or Invested Capital of 0.0 will help investors to properly organize and evaluate Cidara Therapeutics financial condition quickly.
Cidara |
About Cidara Financial Ratios Analysis
Cidara TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Cidara Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Cidara financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Cidara Therapeutics history.
Cidara Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Cidara Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cidara Therapeutics sales, a figure that is much harder to manipulate than other Cidara Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Cidara Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Cidara Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cidara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.At this time, Cidara Therapeutics' Days Sales Outstanding is fairly stable compared to the past year. Capex To Depreciation is likely to rise to 4.49 in 2024, whereas Price To Sales Ratio is likely to drop 1.03 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 55.69 | 12.63 | 14.89 | 14.14 | Receivables Turnover | 9.26 | 11.02 | 3.93 | 3.74 |
Cidara Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Cidara Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cidara Therapeutics fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Ptb Ratio | 3.04 | 7.76 | 3.09 | (18.2) | (8.46) | (8.88) | |
Book Value Per Share | 25.28 | 5.16 | 8.23 | (0.83) | (1.88) | (1.78) | |
Operating Cash Flow Per Share | (19.06) | (26.19) | (9.63) | (8.15) | (5.13) | (5.39) | |
Capex To Depreciation | 0.0933 | 0.81 | (0.0333) | 0.0963 | 4.28 | 4.49 | |
Pb Ratio | 3.04 | 7.76 | 3.09 | (18.2) | (8.46) | (8.88) | |
Free Cash Flow Per Share | (19.09) | (26.28) | (9.64) | (8.19) | (5.25) | (5.51) | |
Roic | (0.84) | (3.86) | (1.73) | 10.33 | 3.61 | 3.79 | |
Net Income Per Share | (26.78) | (34.83) | (16.75) | (8.53) | (5.25) | (5.51) | |
Payables Turnover | 0.18 | 24.59 | 14.89 | 0.0988 | 0.4 | 0.38 | |
Cash Per Share | 40.27 | 17.28 | 23.76 | 9.37 | 8.18 | 7.78 | |
Pocfratio | (4.03) | (1.53) | (2.64) | (1.86) | (3.09) | (3.25) | |
Interest Coverage | (188.8) | (274.23) | (199.32) | (155.59) | (140.03) | (147.03) | |
Capex To Operating Cash Flow | (0.001227) | (0.003418) | (0.001625) | (0.004144) | (0.0225) | (0.0236) | |
Pfcf Ratio | (4.02) | (1.52) | (2.63) | (1.85) | (3.03) | (3.18) | |
Days Payables Outstanding | 14.84 | 24.51 | 2.5K | 3.7K | 903.99 | 1.3K | |
Income Quality | 0.9 | 0.96 | 0.69 | 0.75 | 0.59 | 0.98 | |
Roe | (1.06) | (6.75) | (2.04) | 10.26 | 2.79 | 2.93 | |
Ev To Operating Cash Flow | (2.33) | (1.01) | (0.37) | (0.75) | (1.72) | (1.8) | |
Pe Ratio | (2.87) | (1.15) | (1.52) | (1.77) | (3.03) | (3.18) | |
Return On Tangible Assets | (0.75) | (0.58) | (1.2) | (0.63) | (0.34) | (0.36) | |
Ev To Free Cash Flow | (2.32) | (1.01) | (0.37) | (0.75) | (1.68) | (1.76) | |
Earnings Yield | (0.97) | (0.35) | (0.87) | (0.66) | (0.56) | (0.33) | |
Current Ratio | 2.18 | 1.48 | 2.11 | 1.5 | 0.9 | 0.86 | |
Tangible Book Value Per Share | 25.28 | 5.16 | 8.23 | (0.83) | (1.88) | (1.78) | |
Graham Number | 123.42 | 63.57 | 55.69 | 12.63 | 14.89 | 14.14 | |
Shareholders Equity Per Share | 25.28 | 5.16 | 8.23 | (0.83) | (1.88) | (1.78) | |
Capex Per Share | 0.0234 | 0.0895 | 0.0156 | 0.0338 | 0.12 | 0.11 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.